Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Moving the Industry Towards Automated Systems for Scale-up Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation

Tech Review: New Platforms and Closed-Systems to Enable Commercial Success

27 Jan 2022

13:30  Chairperson’s Opening
Ian Goodwin, Associate Director, Global Program Design, FUJIFILM Diosynth Biotechnologies

13:35 Enabling the Commercial Viability of iPS Cellular Therapies Through Platform Revolution

  • Allogeneic cell therapies are the future and many companies are pursuing this approach
  • The use of iPS cells promises to simplify and further standardize allogeneic cell therapy products as a more “industrialized” product
  • Additional technologies (genetic modification and editing, hypoimmunogenic cells/cloaking) can be implemented at the iPSC level

Anthony Ting, Chief Scientific Officer, Bone Therapeutics

13: 55 Advancing NK Cell Therapy through Feeder-Free Cell Culture Solutions

  • Conjugated antibodies bound to dissolvable microspheres for feeder-free NK cell expansion
  • De-risked processes to seamlessly translate into clinical processes
  • Customizable solutions for effective workflows

Gabriella Perell, Cell and Gene Therapy Product Manager, Bio-Techne

14:15 Unlocking the Full Potential of Cell and Gene Therapies (CGTs) in an Affordable and Accessible Format at the Point of Care

  • The Orgenesis Point-of-Care (“POCare”) Platform is comprised of three enabling components: a pipeline of licensed therapeutics that are processed and produced in closed, automated technology systems across a collaborative network for treating the patient at the point of care.
  • After promising new CGTs are identified, the POCare Platform provides a rapid, globally harmonized pathway for these therapies to reach and treat at the point of care large numbers of patients at lowered costs through efficient, scalable, and decentralized production.
  • OMPULs (Orgenesis Mobile Production Units and Labs) are autonomous production units allowing rapid global deployment and democratization of CGTs. OMPUL technology overcomes conventional processing challenges by enabling high quality, sterile, scalable onsite processing of CGTs

Greg Roumeliotis, Vice President of Global Business Development, Orgenesis

14:35 Speaker Q&A and Panel Discussion


Ian Goodwin
Associate Director, Global Program Design
Fujifilm Diosynth Biotechnologies
Anthony Ting
Chief Scientific Officer
Bone Therapeutics
Gabriella Perell
Cell and Gene Therapy Product Manager
Greg Roumeliotis
Vice President Of Global Business Development